Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H8O4 |
Molecular Weight | 180.1578 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)Oc1ccccc1C(=O)O
InChI
InChIKey=BSYNRYMUTXBXSQ-UHFFFAOYSA-N
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18543581
Curator's Comment:: The penetration of the blood-brain barrier was studied in animals.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11124191
Curator's Comment:: Felix Hoffmann discovered aspirin when working for Friedrich Bayer & Co. # Bayer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P23219|||Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) |
1.2 µM [IC50] | ||
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) |
5.2 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SYNALGOS-DC Approved UseSYNALGOS-DC is a combination of dihydrocodeine, an opioid agonist, aspirin, a nonsteroidal anti-inflammatory drug, and caffeine, a methylxanthine, and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date-3.62620813E11 |
|||
Primary | FIORINAL Approved UseFIORINAL is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Fiorinal in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. Launch Date2.00016003E11 |
|||
Preventing | DURLAZA Approved UseDURLAZA is a nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack. Launch Date1.44132486E12 |
|||
Preventing | AGGRENOX Approved UseAGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Launch Date9.4322878E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
54.25 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.84 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.31 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.12 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.322 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.422 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
68% |
ASPIRIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Sources: https://www.karger.com/Article/Abstract/321727 Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Sources: https://dmd.aspetjournals.org/content/42/6/996.short Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11205285/ Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
no | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
no | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 1242 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 2337 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 278.6 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 40.7 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 683.1 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 698.2 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 94.2 uM] | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Analgesic-induced renal papillary necrosis in the Gunn rat: the comparative nephrotoxicity of aspirin and phenacetin. | 1976 Nov |
|
Acetyl salicylic acid improves somatosensory evoked potentials in streptozotocin-diabetic rats. | 1999 Dec |
|
The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance. | 1999 Dec |
|
Statins and peripheral neuropathy. | 1999 Jan |
|
Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis. | 1999 Jul-Aug |
|
Leptin in gastroprotection induced by cholecystokinin or by a meal. Role of vagal and sensory nerves and nitric oxide. | 1999 Jun 18 |
|
Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation. | 1999 Mar |
|
Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. | 1999 May |
|
Capsaicin-sensitive afferent sensory nerves in modulating gastric mucosal defense against noxious agents. | 1999 Nov |
|
Regular use of analgesics is a risk factor for renal cell carcinoma. | 1999 Oct |
|
Spontaneous compartment syndrome after thrombolytic therapy. | 1999 Sep |
|
Prospective study of aspirin use and risk of stroke in women. | 1999 Sep |
|
Dramatic augmentation of a food allergy by acetylsalicylic acid. | 2000 Apr |
|
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. | 2000 Aug |
|
Pharmacotherapies for cocaine dependence. | 2000 Dec |
|
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. | 2000 Jun |
|
Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. | 2000 Jun 16 |
|
The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation. | 2000 Sep |
|
Novel platelet inhibitors. | 2001 |
|
Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions. | 2001 Feb |
|
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. | 2001 Feb |
|
Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). | 2001 Feb |
|
Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. | 2001 Feb |
|
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. | 2001 Feb 2 |
|
Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior. | 2001 Jan |
|
Present treatment options for unstable angina and non-Q-wave myocardial infarction. | 2001 Jan |
|
Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. | 2001 Jan |
|
Multiple endothelial injury in epicardial coronary artery induces downstream microvascular spasm as well as remodeling partly via thromboxane A2. | 2001 Jan |
|
The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. | 2001 Jan |
|
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols. | 2001 Jan |
|
[Leukocytoclastic vasculitis associated with ticlopidine]. | 2001 Jan |
|
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. | 2001 Jan |
|
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia. | 2001 Jan |
|
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. | 2001 Jan |
|
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. | 2001 Jan |
|
Another reason for taking aspirin. | 2001 Jan |
|
Hypothesized treatment for migraines using low doses of tryptophan, niacin, calcium, caffeine, and acetylsalicylic acid. | 2001 Jan |
|
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. | 2001 Jan |
|
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis. | 2001 Jan 15 |
|
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. | 2001 Jan 23 |
|
The basis of prostaglandin synthesis in coral: molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa. | 2001 Mar 9 |
Sample Use Guides
Severe pain: Initiate treatment with two capsules (1 capsule contains 16 mg dihydrocodeine bitartrate, 356.4 mg aspirin, and 30 mg caffeine) orally every 4 hours as needed for pain. Headache: One or 2 capsules (1 capsule contains 50 mg butalbital, 325 mg aspirin and 40 mg caffeine) every 4 hours. Total daily dose should not exceed 6 capsules. Prevention of stoke and heart attacks: the recommended dose is one capsule of aspirin (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day. Prevention of stroke (in combination with dipyridamole): the recommended dose is one capsule (200 mg dipyridamole and 25 mg aspirin) given orally twice daily.
Route of Administration:
Enteral
Human platelet-rich plasma was incubated with various aspirin concentrations (10, 20, 50, 100, 200, 300, 400, 500 uM) at 37C for up to 4.5 h. Platelet aggregation and thromboxane generation were measured. Inhibition of platelet aggregation and thromboxane formation by 10 uM aspirin was maximal by 90 min. There was progressive inhibition by 3 uM aspirin during incubation for 270 min. By the end of this time there was also significant inhibition by 1 uM aspirin.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C07FX02
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
CFR |
21 CFR 343.13
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
CFR |
21 CFR 343.12
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QN02BA51
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
C10BX01
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QB01AC56
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
LIVERTOX |
68
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
C10BX05
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
A01AD05
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QM01BA03
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
DUOCOVER (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
M01BA03
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
FDA ORPHAN DRUG |
724719
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
C10BX04
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL/ACETYLSALICYLIC ACID (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL/ACETYLSALICYCLIC ACID (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
N02AJ02
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
FDA ORPHAN DRUG |
764120
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QN02BA71
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QB01AC06
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
DUOPLAVIN (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QC10BX05
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
NDF-RT |
N0000008836
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
NDF-RT |
N0000000160
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
DUOPLAVIN (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.5
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
NDF-RT |
N0000008836
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
N02BA71
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
N02BA01
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
FDA ORPHAN DRUG |
724619
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QC10BX02
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
FDA ORPHAN DRUG |
607917
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
C10BX08
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
NDF-RT |
N0000175722
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
CFR |
21 CFR 520.1409
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
B01AC08
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
B01AC56
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
EU-Orphan Drug |
EU/3/04/208
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
N02BA51
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
B01AC06
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
C10BX06
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
N02BA15
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QA01AD05
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
C10BX02
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
C10BX12
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
NDF-RT |
N0000175721
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
NDF-RT |
N0000175578
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
N02AJ07
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QC10BX01
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
N02AJ18
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
EPA PESTICIDE CODE |
129061
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
7.1
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
2.1
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
CFR |
21 CFR 341.40
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
C07FX03
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
C07FX04
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QN02BA01
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
DUOCOVER (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-VATC |
QC10BX04
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
||
|
WHO-ATC |
N02BA65
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00945
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
D001241
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
200-064-1
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
2244
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
C287
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
R16CO5Y76E
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
652
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
1044006
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | USP-RS | ||
|
1191
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
50-78-2
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
74
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
91101
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
ALTERNATIVE | |||
|
SUB12730MIG
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
M2111
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | Merck Index | ||
|
4139
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
ASPIRIN
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
ASPIRIN
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless or almost odourless. Solubility: Soluble in about 300 parts of water; freely soluble in ethanol (~750 g/l) TS; soluble in ether R. Category: Analgesic; antipyretic. Storage: Acetylsalicylic acid should be kept in a tightly closed container, protected from light. Additional information: Even in the absence of light, Acetylsalicylic acid is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Acetylsalicylic acid contains not less than 99.0% and not more than 100.5% of C9H8O4, calculated with reference to the dried substance. | ||
|
Aspirin
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
CHEMBL25
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY | |||
|
50-78-2
Created by
admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)